Povorcitinib - JAK1 specific for Hidradenitis Suppurativa Efficacy at 16 weeks, improvement of disease and draining tunnel count over PBO Upadacitinib shown with benefit for HS, but not as dramatic JAK response as other derm conditions #RNL2024 @RheumNow https://t.co/f2cxJbLi1I